SAB Biotherapeutics, Inc. (SABS) Institutional Ownership

Ownership Summary

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has 48 institutional investors with active 13F positions as of December 2025.

• They owned 46.7% of outstanding stock in December 2025, up from 36.0% the prior quarter.
• They increased total shares held in SAB Biotherapeutics by 37.82% from last quarter, and the number of investors in SABS increased 84.62% annually.
• During the quarter, 32 of these 48 funds increased positions in SABS, 4 reduced exposure, and 12 held steady.
• In total, institutional investors held 36.37Mn shares in SAB Biotherapeutics as of December 2025, up by 9.98Mn shares quarter on quarter, and up 33.7Mn shares year over year.
• As of December 31, 2025, Vivo Capital, LLC held the largest stake in SAB Biotherapeutics with 11.42Mn shares, accounting for 14.67% of total shares outstanding.
• The largest buyers of SAB Biotherapeutics for the quarter ending December 2025 were Spruce Street Capital LP (2.2Mn), Blackstone Inc. (2.14Mn), VANGUARD GROUP INC (1.48Mn), PERCEPTIVE ADVISORS LLC (803.21K), Propel Bio Management, LLC (652.88K).
• The largest sales of SABS for the quarter ending December 2025 came from UBS Group AG (5.82K), CAXTON CORP (408), Kestra Advisory Services, LLC (380), SBI Securities Co., Ltd. (2).
• Per Business Quant, the top 10 investors in SABS for the quarter ending December 2025 include Vivo Capital, LLC (11.42Mn), RA CAPITAL MANAGEMENT, L.P. (4.4Mn), Commodore Capital LP (4.4Mn), Woodline Partners LP (2.85Mn), Spruce Street Capital LP (2.2Mn), Sessa Capital IM, L.P. (2.2Mn), Blackstone Inc. (2.14Mn), VANGUARD GROUP INC (1.85Mn), PERCEPTIVE ADVISORS LLC (803.21K), Propel Bio Management, LLC (652.88K).